Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%. Investors are beginning to scoff at its expensive price tag, with Eli Lilly trading ...

Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in ...

Eli Lilly's next-generation products look promising, while competitors have stumbled in clinical trials. Investors are paying up to own the stock. The competitive landscape for GLP-1 agonist ...

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.

Eli Lilly (LLY ... such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued ...

Eli Lilly shares jumped ... according to Lilly. mbruxelle – stock.adobe.com One of the main barriers to wider adoption of current GLP-1 therapies, such as Ozempic and Wegovy, has been their ...

Eli Lilly's stock boomed April 17 after announcing a new ... Lilly's shares had increased roughly 16% by 1 p.m. ET after the results of the trial were released. Lilly said its new pill would ...

Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable weight-loss and diabetes drugs. One thing hampering the GLP-1 drug boom is the ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

today's valuation and price could still look cheap years from now. As long as you are willing to be patient, now may be an excellent time to add Eli Lilly stock to your portfolio. David Jagielski ...